Synercid Drug

Advisors to the Food and Drug Administration voted Thursday to recommend limited approval of the first new antibiotic designed to battle drug-resistant bacteria. The recommendation comes just months after doctors discovered that strains of the common Staphylococcus germ are developing resistance to today's antibiotic of last resort, vancomycin. Synercid, developed by Rhone-Poulenc Rorer Inc., is the first of a new class of antibiotics called streptogramins.

Advisors to the Food and Drug Administration voted Thursday to recommend limited approval of the first new antibiotic designed to battle drug-resistant bacteria. The recommendation comes just months after doctors discovered that strains of the common Staphylococcus germ are developing resistance to today's antibiotic of last resort, vancomycin. Synercid, developed by Rhone-Poulenc Rorer Inc., is the first of a new class of antibiotics called streptogramins.